[{"orgOrder":0,"company":"Greenwich Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"CB1\/2 receptor","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Greenwich Biosciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Greenwich Biosciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Greenwich Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Greenwich Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"Tetrahydrocannabinol","moa":"||CB1\/CB2 receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Greenwich Biosciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oromucosal Spray","sponsorNew":"Greenwich Biosciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Greenwich Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Greenwich Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"Tetrahydrocannabinol","moa":"||CB1\/CB2 receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Greenwich Biosciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oromucosal Spray","sponsorNew":"Greenwich Biosciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Greenwich Biosciences \/ Inapplicable"}]

Find Clinical Drug Pipeline Developments & Deals by Greenwich Biosciences

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          PEGS Boston Summit
                          Not Confirmed
                          PEGS Boston Summit
                          Not Confirmed

                          Details : Data from three randomized, placebo-controlled trials of nabiximols (GWMS0106, GWSP0604, and SAVANT) conducted were analyzed to assess the relationship between measures of spasticity and muscle strength in lower extremities or walking speed.

                          Product Name : Nabiximols

                          Product Type : Controlled Substance

                          Upfront Cash : Inapplicable

                          November 13, 2020

                          Lead Product(s) : Tetrahydrocannabinol,Cannabidiol

                          Therapeutic Area : Neurology

                          Highest Development Status : Approved FDF

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          PEGS Boston Summit
                          Not Confirmed
                          PEGS Boston Summit
                          Not Confirmed

                          Details : Results from post-hoc analysis of phase 3 clinical study show nabiximols was well-tolerated and provided continued reductions in spasticity for individuals who remained on therapy.

                          Product Name : Nabiximols

                          Product Type : Controlled Substance

                          Upfront Cash : Inapplicable

                          October 09, 2020

                          Lead Product(s) : Tetrahydrocannabinol,Cannabidiol

                          Therapeutic Area : Neurology

                          Highest Development Status : Approved FDF

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          PEGS Boston Summit
                          Not Confirmed
                          PEGS Boston Summit
                          Not Confirmed

                          Details : Epidiolex (cannabidiol), is a prescription, plant-derived cannabis-based medicine which is act CB receptor agonist, administered as an oral solution which contains highly purified cannabidiol (CBD), which is used for Lennox-Gastaut Syndrome and Dravet sy...

                          Product Name : Epidiolex

                          Product Type : Controlled Substance

                          Upfront Cash : Inapplicable

                          March 08, 2020

                          Lead Product(s) : Cannabidiol

                          Therapeutic Area : Rare Diseases and Disorders

                          Highest Development Status : Approved FDF

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank